Meropenem in Pseudomonas Infections: Action, Resistance, and Synergy

Meropenem kills Pseudomonas aeruginosa by disabling the enzymes the bacterium needs to build and maintain its cell wall, but Pseudomonas has an unusually deep toolbox of ways to neutralize or evade the drug. This tension between a potent carbapenem antibiotic and one of the most adaptable pathogens in clinical medicine shapes nearly every treatment decision involving the pair. How the drug enters the bacterial cell, how it is dosed, why resistance keeps emerging, and which partner drugs can tip the balance back in the clinician’s favor are all pieces of a single puzzle.

How Meropenem Enters the Cell and Reaches Its Target

Meropenem belongs to the carbapenem class of beta-lactam antibiotics. Like all beta-lactams, it works by binding to penicillin-binding proteins (PBPs), which are enzymes embedded in the bacterial inner membrane that cross-link the peptidoglycan strands forming the cell wall. When meropenem locks onto these PBPs, cross-linking stalls, the wall weakens, and the bacterium ruptures under its own internal pressure. Research profiling PBP occupancy in P. aeruginosa PAO1 has shown that meropenem’s binding improves when the bacterium’s outer-membrane efflux channel OprM is knocked out, confirming that efflux directly reduces the amount of drug reaching those targets.¹

Before meropenem can bind PBPs, though, it first has to cross the outer membrane of this Gram-negative organism. The primary gateway is a porin channel called OprD. Carbapenems use OprD as their main route into the periplasmic space, the compartment between the outer and inner membranes where PBPs sit.² However, early work also suggested meropenem can slip through alternative routes when OprD is absent, which partly explains why Pseudomonas strains that lose OprD become highly resistant to imipenem (another carbapenem that relies almost exclusively on that channel) yet sometimes retain marginal susceptibility to meropenem.

Why Infusion Time Matters More Than You Might Expect

Meropenem’s effectiveness is driven by how long its concentration stays above the minimum inhibitory concentration (MIC) of the infecting organism. In pharmacology shorthand, this is described as a “time-dependent” kill pattern. The clinical goal is to keep free drug levels above the MIC for a sufficient percentage of each dosing interval. A case report of septic shock caused by extensively drug-resistant P. aeruginosa demonstrated cure when the meropenem regimen was tailored so that drug levels exceeded four times the MIC for at least 40% of the interval between doses.³

Standard meropenem infusions run over about 30 minutes. Extending that infusion time to three hours, or even switching to a continuous drip, keeps drug levels above the MIC for a much larger fraction of the dosing interval. Pharmacokinetic modeling has shown that a high-dose prolonged-infusion regimen of 2 grams every eight hours infused over three hours can achieve adequate drug exposure against Pseudomonas strains with MICs up to 16 micrograms per milliliter.⁴ Modeling work comparing standard half-hour infusions with three-hour or continuous infusions found that prolonged infusion and continuous infusion with a loading dose were both superior at 24 hours, particularly at higher MIC values.⁵

The practical payoff of extended infusion is most visible against tougher strains. In biofilm experiments comparing intermittent bolus dosing with extended-infusion meropenem against both a reference strain and a highly resistant clinical isolate, the extended-infusion approach produced substantially greater bacterial killing for the reference strain and was the only effective regimen against the resistant one, where the bolus strategy failed entirely.⁶ A large retrospective study of patients with P. aeruginosa bloodstream infections found that those whose dosing regimens achieved a high probability of meeting the pharmacodynamic target had dramatically better in-hospital survival, with an adjusted odds ratio above 20.⁷

Three Resistance Strategies Pseudomonas Deploys Against Meropenem

Pseudomonas aeruginosa does not typically rely on a single trick to resist carbapenems. Instead, resistance usually emerges through overlapping mechanisms, and their relative contribution varies by strain and region. The three main categories are porin loss, efflux pump overexpression, and enzyme-mediated drug destruction.

Shutting the Door With OprD Loss

The most straightforward route to carbapenem resistance is closing the front door. Mutations in the gene encoding OprD, the main porin channel for carbapenems, can produce a truncated or misfolded protein that no longer lets the drug through. Structural changes in the channel’s internal loops can also narrow passage enough to block entry.⁸ A recent study of carbapenem-resistant P. aeruginosa strains found extensive amino acid mutations and premature stop signals in the OprD gene, including, for the first time, the insertion of a mobile genetic element (IS256) that disrupted the gene. Those strains carried no detectable carbapenemases and showed no upregulation of efflux pumps, meaning OprD loss alone was sufficient to confer carbapenem resistance. Restoring normal OprD expression reversed that resistance completely.⁹

OprD loss hits imipenem harder than meropenem, because imipenem depends on OprD almost exclusively. Meropenem can exploit alternative entry pathways to some degree, so OprD loss may raise the MIC without pushing it above the resistance breakpoint in every case. Still, OprD deficiency is consistently one of the most common findings in meropenem-resistant clinical isolates.

Pumping the Drug Back Out

P. aeruginosa carries multiple efflux pump systems that actively expel antibiotics from the periplasm before they can reach their targets. The MexAB-OprM pump is constitutively expressed at significant levels and is a major contributor to both intrinsic and acquired resistance to meropenem.¹⁰ A study of meropenem-resistant but ceftazidime-susceptible P. aeruginosa isolates from a region where metallo-beta-lactamases were common found that overexpression of MexAB-OprM, detected via the mexB gene, was present in the majority of isolates, with MexXY-OprM overexpression (via mexY) also contributing in a subset.¹¹ In one investigation of a Japanese hospital, dual resistance to fluoroquinolones and carbapenems was linked to both OprD premature stop codons and mexY overexpression occurring in the same isolates.¹²

A Spanish study of carbapenem-resistant clinical isolates quantified how often these mechanisms overlapped. Among resistant strains, mexB overexpression was the single most common finding at about 63%, followed by mexY overexpression at roughly 53%, ampC overexpression at about 37%, and reduced OprD expression at around 21%.¹³ The numbers illustrate that most resistant strains carry more than one mechanism at once, stacking the odds against any single antibiotic.

Enzymatic Destruction With Carbapenemases

The most alarming resistance mechanism is production of carbapenemases, enzymes that chemically break apart the carbapenem ring and render the drug inactive. Among P. aeruginosa, the most clinically relevant carbapenemases are the metallo-beta-lactamases (MBLs), which use zinc ions to catalyze the reaction. A Swiss molecular survey of MBL-producing P. aeruginosa from 2022 to 2023 found VIM-type enzymes in about 54% of isolates, NDM-type in roughly 28%, and IMP-type in about 15%.¹⁴ A large Polish dataset of over 450 MBL-producing isolates showed even heavier dominance of VIM enzymes, with VIM-2 alone accounting for about two-thirds of all MBLs detected.¹⁵ These enzymes are carried on mobile genetic elements, meaning they can spread between strains and species, and they confer resistance not only to meropenem but also to most other beta-lactams and newer beta-lactam/beta-lactamase-inhibitor combinations.

Heteroresistance and Why a “Susceptible” Label Can Be Misleading

Standard susceptibility testing reports a single MIC value for a given isolate, treating the entire bacterial population as uniform. In reality, a subset of cells within an otherwise susceptible population may carry heritable resistance that lets them survive drug exposure. This phenomenon, called heteroresistance, can cause strains to test as susceptible in the lab but fail therapy in the patient. A study screening 170 clinical P. aeruginosa isolates found that heteroresistance to meropenem was among the most common patterns detected.¹⁶

How prevalent is this? In a temporal analysis of clinical isolates, about half showed heteroresistance to meropenem or piperacillin-tazobactam on confirmatory testing, with meropenem heteroresistance peaking at roughly 35% in one period before declining somewhat in subsequent years.¹⁷ Because routine susceptibility tests do not flag heteroresistance, it can contribute to unexplained treatment failures. Research into diagnostic models for detecting meropenem heteroresistance in P. aeruginosa highlights the gap between what a standard lab report says and what is actually happening in the patient.¹⁸

Synergy With Aminoglycosides

Combining meropenem with an aminoglycoside like tobramycin or amikacin is one of the oldest and most studied strategies for difficult Pseudomonas infections. The rationale is straightforward: beta-lactams weaken the cell wall, which may improve aminoglycoside entry into the cytoplasm, where it disrupts ribosomal protein synthesis. In vitro checkerboard testing of meropenem paired with amikacin, arbekacin, or netilmicin showed synergistic or additive effects against nearly all tested P. aeruginosa strains, including meropenem-resistant ones, with no antagonism detected.¹⁹

Where the combination shows the most promise is in biofilm settings, particularly relevant for cystic fibrosis lung infections. When tested individually, both meropenem and tobramycin monotherapy failed to suppress regrowth of hypermutable P. aeruginosa in a dynamic biofilm model, with planktonic counts rebounding above six log units and resistance emerging rapidly. A combination using continuous-infusion meropenem with tobramycin synergistically suppressed both total planktonic regrowth and resistance emergence in both planktonic and biofilm bacteria.²⁰ Mathematical modeling of this combination has confirmed that high-dose regimens can suppress resistant subpopulations for extended periods, though resistance eventually emerges even with the combination against some isolates.²¹

Synergy With Colistin

When strains resist both meropenem and aminoglycosides, colistin (polymyxin E) is often the remaining option. Colistin disrupts the outer membrane of Gram-negative bacteria by binding to its lipopolysaccharide layer. The hypothesis behind combining it with meropenem is that colistin’s membrane damage creates new openings for meropenem to reach the periplasm, bypassing porin loss and potentially overwhelming efflux capacity.²²

The evidence on this combination is mixed depending on how you measure it. Dynamic time-kill experiments found that colistin plus meropenem enhanced early bacterial killing in some P. aeruginosa strains and produced statistically significant reductions in overall bacterial burden for a subset, but traditional checkerboard testing did not identify synergy for any of the tested strains.²³ This discrepancy reflects a broader issue in synergy testing: static methods like checkerboards and dynamic time-kill approaches can reach different conclusions for the same drug pair. Pharmacokinetic/pharmacodynamic modeling predicts that a loading dose of colistin combined with high-dose meropenem (2 grams every eight hours) can produce pronounced killing even of meropenem-resistant strains over 24 hours, supporting the use of aggressive combination dosing in clinical practice.²⁴

Beta-Lactamase Inhibitor Partnerships

A newer approach pairs meropenem with vaborbactam, a boronic-acid-based beta-lactamase inhibitor originally developed to counter serine carbapenemases in Enterobacterales. Against P. aeruginosa, vaborbactam’s utility is more limited because the predominant carbapenemases in this species are metallo-beta-lactamases, which vaborbactam does not inhibit. However, vaborbactam can inhibit the chromosomally encoded AmpC cephalosporinase that P. aeruginosa naturally produces. In isolates where AmpC overexpression and MexXY efflux pump upregulation drive resistance, adding vaborbactam has been shown to lower meropenem MICs.²⁵

In animal infection models, meropenem-vaborbactam regimens simulating three-hour infusions achieved bacterial killing against P. aeruginosa strains with MICs up to 16 micrograms per milliliter.²⁶ A surveillance study of skin and soft tissue infections found the combination active against about 94% of P. aeruginosa isolates.²⁷ The picture is less rosy when MBL-producing strains are involved: the Swiss molecular survey found that all MBL-producing isolates resisted meropenem-vaborbactam, along with every other currently available beta-lactam/inhibitor combination.¹⁴

Dosing Challenges in Patients With Fast-Clearing Kidneys

Meropenem is cleared almost entirely by the kidneys. In critically ill patients with augmented renal clearance (ARC), where the kidneys filter blood much faster than normal, drug levels can drop below the target threshold well before the next dose. This is not a rare scenario: ARC is common in younger, severely injured, or septic ICU patients.

Monte Carlo simulations for patients with creatinine clearance of 140 to 200 milliliters per minute found that the standard high-dose regimen of 2 grams every eight hours, even infused over two to three hours, only achieved adequate drug exposure against P. aeruginosa with low MICs of 2 micrograms per milliliter or less. For organisms with MICs of 4 to 8, intensified approaches like four- to six-hour infusions or continuous infusion were necessary.²⁸ A separate simulation study specifically focused on P. aeruginosa infections in ARC patients recommended 2 grams every six hours as the empirical regimen to reach pharmacodynamic targets, with an even higher dose of 3 grams every six hours recommended to suppress resistance development.²⁹ Simply extending the infusion time without increasing the total dose was not enough in these patients.

These findings underscore the emerging role of therapeutic drug monitoring and model-informed dosing in critically ill populations, where a one-size-fits-all regimen frequently underdoses some patients and overdoses others.³⁰

What Happens at Sub-Inhibitory Concentrations

Meropenem levels inevitably dip below the MIC during some parts of the dosing interval, and what happens during those troughs is clinically relevant. Sub-inhibitory concentrations of meropenem have been shown to reduce several virulence-related behaviors in P. aeruginosa, including the production of pyocyanin (a toxic pigment), proteolytic enzyme activity, and biofilm formation. These effects were observed in both wild-type strains and several quorum-sensing mutants. Interestingly, the loss of both major quorum-sensing regulatory components simultaneously made strains more sensitive to meropenem, suggesting these cell-communication systems play some role in the bacterium’s tolerance of the drug.³¹

The effect on biofilm was not universal, however. One double quorum-sensing mutant actually increased biofilm production when exposed to sub-MIC meropenem, a reminder that drug-bug interactions at low concentrations are strain-dependent and not always in the clinician’s favor.

Reaching the Brain

Meropenem is sometimes needed for central nervous system infections, including ventriculitis and meningitis caused by P. aeruginosa. Getting adequate drug into the cerebrospinal fluid (CSF) is a challenge. A prospective study in neurocritical-care patients found that CSF penetration was poor, with a median CSF-to-serum ratio of about 9% and high variability between individuals.³²

Given how low that penetration rate is, clinicians sometimes assume continuous infusion will achieve higher CSF levels than intermittent dosing. A more recent prospective cohort study tested exactly that and found no meaningful difference in CSF concentrations between continuous and intermittent infusion strategies. The strongest predictor of improved penetration was the degree of CNS inflammation, as measured by interleukin-6 levels in the CSF, not the infusion mode.³³ In practical terms, the inflamed meninges that accompany active infection allow more drug through, so meropenem tends to work best in the CNS precisely when the infection is most active and the barrier most leaky. As inflammation subsides with treatment, penetration drops, creating a therapeutic window that narrows as the patient improves.